US2021115104A1PendingUtilityA1
Amylin analogues
Est. expiryMar 18, 2035(~8.6 yrs left)· nominal 20-yr term from priority
Inventors:Rasmus JustOliver DemmerLise GiehmJesper Skodborg VilladsenHenrik Kofoed MunchJesper Mosolff MathiesenJolanta SkarbalieneMaria Alexandrovna DeryabinaDieter Hamprecht
C07K 14/47A61K 38/00A61P 3/00C07K 14/575A61P 3/04A61P 43/00A61P 3/10
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
Claims
exact text as granted — not AI-modified1 . An amylin analogue which is a compound having the formula:
R 1 —Z—R 2
wherein R 1 is hydrogen, C 1-4 acyl, benzoyl or C 1-4 alkyl, or a half-life extending moiety M, wherein M is optionally linked to Z via a linker moiety L; R 2 is OH or NHR 3 , wherein R 3 is hydrogen or C 1-3 -alkyl; and Z is an amino acid sequence of formula I:
(SEQ ID NO: 3)
Arg-Cys-X3-Thr-Ala-Thr-Cys-Ala-Thr-X10-Arg-Leu-
Ala-X14-Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-
Ile(Me)-Leu-Ser-Ser-Thr-X31-Val-Gly-Ser-X35-Thr-
X37
(I);
wherein
X3 is selected from the group consisting of Asn, Gly, Pro and Gln;
X10 is selected from the group consisting of Gln, Asp and Glu;
X14 is selected from the group consisting of Asp, His, Asn and Aad;
X17 is selected from the group consisting of His, Asn, Gln, Glu, Thr, Val, Lys and Aad;
X19-X20 is selected from the group consisting of Ser-Ser, Val-Val, Ser-Val and Val-Ser, or is absent;
X31 is selected from the group consisting of Asp, Glu and Asn;
X35 is selected from the group consisting of Asp, Glu, Asn, Ser, Phe, Orn, Aad, Gly and Thr; and
X37 is selected from the group consisting of Pro, Apr and Hyp;
and wherein the compound has at least one residue selected from:
X3 is Gln;
X14 is His, Asn or Aad;
X17 is Asn, Gln, Glu, Thr or Aad;
X19-X20 is Val-Ser or Ser-Val; and
X35 is Ser, Phe, Orn, Aad, Gly or Thr;
or a pharmaceutically acceptable salt thereof.
2 - 4 . (canceled)
5 . An amylin analogue according to claim 1 wherein Z is an amino acid sequence of formula II:
(SEQ ID NO: 4)
Arg-Cys-X3-Thr-Ala-Thr-Cys-Ala-Thr-X10-Arg-Leu-
Ala-X14-Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-
Ile(Me)-Leu-Ser-Ser-Thr-Glu-Val-Gly-Ser-X35-Thr-
X37
(II);
wherein
X3 is selected from the group consisting of Asn, Gly and Gln;
X10 is selected from the group consisting of Gln, Asp and Glu;
X14 is selected from the group consisting of Asp, His and Aad;
X17 is selected from the group consisting of His, Asn, Gln, Glu, Lys and Aad;
X19-X20 is Ser-Ser or is absent;
X35 is selected from the group consisting of Asp, Glu, Asn, Ser, Orn, Aad, Gly and Thr; and
X37 is selected from the group consisting of Pro and Hyp;
and wherein the compound has at least one residue selected from:
X3 is Gln;
X14 is His or Aad;
X17 is Asn, Gln, Glu or Aad; and
X35 is Ser, Phe, Orn, Aad, Gly or Thr.
6 . (canceled)
7 . An amylin analogue according to claim 1 wherein Z is an amino acid sequence of formula III:
(SEQ ID NO: 5)
Arg-Cys-X3-Thr-Ala-Thr-Cys-Ala-Thr-X10-Arg-Leu-
Ala-X14-Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-
Ile(Me)-Leu-Ser-Ser-Thr-Glu-Val-Gly-Ser-X35-
Thr-X37
(III);
wherein
X3 is selected from the group consisting of Asn, Gly and Gln;
X10 is selected from the group consisting of Gln, Asp and Glu;
X14 is selected from the group consisting of Asp, His and Aad;
X17 is selected from the group consisting of His and Gln;
X19-X20 is Ser-Ser or is absent;
X35 is selected from the group consisting of Asp, Glu, Asn, Aad and Gly; and
X37 is selected from the group consisting of Pro and Hyp;
and wherein the compound has at least one residue selected from:
X3 is Gln;
X14 is His or Aad;
X17 is Gln; and
X35 is Aad.
8 - 17 . (canceled)
18 . An amylin analogue according to claim 1 wherein Z is:
(SEQ ID NO: 6)
RCNTATCATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSETP,
(SEQ ID NO: 7)
RCNTATCATQRLANFLHRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSETP,
(SEQ ID NO: 8)
RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 9)
RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 10)
RCGTATCATERLAHFLERSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 11)
RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSST-Hyp,
(SEQ ID NO: 12)
RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSFT-Hyp,
(SEQ ID NO: 13)
RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGS-Orn-T-Hyp,
(SEQ ID NO: 14)
RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGS-Aad-T-Hyp,
(SEQ ID NO: 15)
RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSGT-Hyp,
(SEQ ID NO: 16)
RCNTATCATQRLAHFLHRF-Gly(Me)-A-Ile(Me)-
LSSTEVGSETP,
(SEQ ID NO: 17)
RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNTP,
(SEQ ID NO: 18)
RCNTATCATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNTP,
(SEQ ID NO: 19)
RCGTATCATERLANFLVRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 20)
RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 21)
RCGTATCATERLAHFLKRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 22)
RCNTATCATQRLAHFLHRSVF-Gly(Me)-A-Ile(Me)-
LSSTEVGSETP,
(SEQ ID NO: 23)
RCNTATCATQRLAHFLHRVSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSETP,
(SEQ ID NO: 24)
RCGTATCATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSETP,
(SEQ ID NO: 25)
RCPTATCATDRLAHFLVRSSF-Gly(Me)-A-Ile(Me)-
LSSTDVGSDTP,
(SEQ ID NO: 26)
RCNTATCATQRLAHFLVRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSETP,
(SEQ ID NO: 27)
RCPTATCATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-
LSSTDVGSNTP,
(SEQ ID NO: 28)
RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSETP,
(SEQ ID NO: 29)
RCPTATCATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-
LSSTDVGSDTP,
(SEQ ID NO: 30)
RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSST-Hyp,
(SEQ ID NO: 31)
RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSST-Hyp,
(SEQ ID NO: 32)
RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSST-Hyp,
(SEQ ID NO: 33)
RCGTATCATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSST-Hyp,
(SEQ ID NO: 34)
RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSFT-Hyp,
(SEQ ID NO: 35)
RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSFT-Hyp,
(SEQ ID NO: 36)
RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSSTP,
(SEQ ID NO: 37)
RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSSTP,
(SEQ ID NO: 38)
RCGTATCATERLAHFLERSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSSTP,
(SEQ ID NO: 39)
RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSSTP,
(SEQ ID NO: 40)
RCGTATCATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSSTP,
(SEQ ID NO: 41)
RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSFTP,
(SEQ ID NO: 42)
RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSFTP,
(SEQ ID NO: 43)
RCGTATCATERLADFLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSST-Hyp,
(SEQ ID NO: 44)
RCGTATCATERLADFLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSFT-Hyp,
(SEQ ID NO: 45)
RCGTATCATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSST-Hyp,
(SEQ ID NO: 46)
RCGTATCATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGS-Orn-T-Hyp,
(SEQ ID NO: 47)
RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSST-Apr,
(SEQ ID NO: 48)
RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSSTP,
(SEQ ID NO: 49)
RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGS-Orn-TP,
(SEQ ID NO: 50)
RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSTT-Hyp,
(SEQ ID NO: 51)
RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 52)
RCNTATCATQRLAHFL-Aad-RSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 53)
RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGS-Orn-T-Hyp,
(SEQ ID NO: 54)
RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSGT-Hyp,
(SEQ ID NO: 55)
RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGS-Aad-T-Hyp,
(SEQ ID NO: 56)
RCGTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 57)
RCGTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 58)
RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 59)
RCQTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 60)
RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 61)
RCPTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTDVGSNT-Hyp,
(SEQ ID NO: 62)
RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSDT-Hyp,
(SEQ ID NO: 63)
RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNTP,
(SEQ ID NO: 64)
RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNTP,
(SEQ ID NO: 65)
RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 66)
RCPTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 67)
RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNTP,
(SEQ ID NO: 68)
RCNTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNTP,
(SEQ ID NO: 69)
RCPTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNTP,
(SEQ ID NO: 70)
RCNTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 71)
RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSST-Hyp,
(SEQ ID NO: 72)
RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSST-Hyp,
(SEQ ID NO: 73)
RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSGT-Hyp,
(SEQ ID NO: 74)
RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSGT-Hyp,
(SEQ ID NO: 75)
RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSTT-Hyp,
(SEQ ID NO: 76)
RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSTT-Hyp,
(SEQ ID NO: 77)
RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGS-Aad-T-Hyp,
(SEQ ID NO: 78)
RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGS-Aad-T-Hyp,
(SEQ ID NO: 79)
RCGTATCATERLAHFLQRF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 80)
RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNTP,
(SEQ ID NO: 81)
RCNTATCATQRLAHFLQRF-Gly(Me)-A-Ile(Me)-
LSSTEVGSGT-Hyp,
(SEQ ID NO: 82)
RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSGTP,
(SEQ ID NO: 83)
RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSGT-Hyp,
(SEQ ID NO: 84)
RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSTTP,
(SEQ ID NO: 85)
RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSTT-Hyp,
(SEQ ID NO: 86)
RCNTATCATQRLAHFLERSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSSTP,
(SEQ ID NO: 87)
RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSSTP,
(SEQ ID NO: 88)
RCNTATCATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 89)
RCNTATCATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSST-Hyp,
(SEQ ID NO: 90)
RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 91)
RCQTATCATDRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
(SEQ ID NO: 92)
RCQTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSGT-Hyp,
(SEQ ID NO: 93)
RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSGT-Hyp,
(SEQ ID NO: 94)
RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNTP,
(SEQ ID NO: 95)
RCQTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNTP,
(SEQ ID NO: 96)
RCQTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSGTP,
(SEQ ID NO: 97)
RCQTATCATDRLA-Aad-FLQRF-Gly(Me)-A-Ile(Me)-
LSSTEVGSNT-Hyp,
or
(SEQ ID NO: 98)
RCQTATCATERLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP.
19 . An amylin analogue which is a compound having the formula:
R 1 —Z—R 2
wherein R 1 is hydrogen, C 1-4 acyl, benzoyl or C 1-4 alkyl, or a half-life extending moiety M, wherein M is optionally linked to Z via a linker moiety L; R 2 is OH or NHR 3 , wherein R 3 is hydrogen or C 1-3 -alkyl; and Z is an amino acid sequence selected from the group consisting of:
(SEQ ID NO: 99)
RCNTATCATQRLADFLHRSSF-Gly(Me)-A-Ile(Me)-
LSSTEVGSETP;
(SEQ ID NO: 100)
RCNTATCATQRLADFLHRSSNNF-Gly(Me)-A-Ile(Me)-
LSSTNVGSNT-Apr;
and
(SEQ ID NO: 101)
RCNTATCATQRLAHFLHRSSNNF-Gly(Me)-A-Ile(Me)-
LSSTNVGSNT-Apr;
or a pharmaceutically acceptable salt or thereof.
20 . An amylin analogue according to claim 1 wherein R 1 is M- or M-L-.
21 . An amylin analogue according to claim 20 , wherein M is an alkanoyl group.
22 . An amylin analogue according to claim 21 , wherein M is selected from 15-carboxy-pentadecanoyl, 17-carboxy-heptadecanoyl and 19-carboxy-nonadecanoyl.
23 . An amylin analogue according to claim 1 wherein R 1 is M-L- and L is a residue of an amino acid selected from the group consisting of Gly, Pro, Ala, Val, Leu, Ile, Met, Cys, Phe, Tyr, Trp, His, Lys, Arg, Gln, Asn, α-Glu, γ-Glu, ε-Lys, Asp, β-Asp, Ser, Thr, Gaba, Aib, β-Ala, 4-aminobutanoyl, 5-aminopentanoyl, 6-aminohexanoyl, 7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl, 10-aminodecanoyl and 8Ado.
24 . An amylin analogue according to claim 23 wherein L is a γ-Glu residue.
25 . An amylin analogue according to claim 1 wherein R 2 is NH 2 .
26 . An amylin analogue according to claim 1 which is selected from the group consisting of:
(SEQ ID NO: 103)
[19CD]-isoGlu-RCNTATCATQRLAHFLHRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSETP-NH 2 ,
(SEQ ID NO: 104)
[19CD]-isoGlu-RCNTATCATQRLANFLHRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSETP-NH 2 ,
(SEQ ID NO: 107)
[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 108)
[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 109)
[19CD]-isoGlu-RCGTATCATERLAHFLERSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 110)
[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSST-Hyp-NH 2 ,
(SEQ ID NO: 111)
[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSFT-Hyp-NH 2 ,
(SEQ ID NO: 112)
[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH 2 ,
(SEQ ID NO: 113)
[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH 2 ,
(SEQ ID NO: 114)
[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSGT-Hyp-NH 2 ,
(SEQ ID NO: 115)
[19CD]-isoGlu-RCNTATCATQRLAHFLHRF-Gly(Me)-A-
Ile(Me)-LSSTEVGSETP-NH 2 ,
(SEQ ID NO: 116)
[19CD]-isoGlu-RCGTATCATERLAHFLHRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNTP-NH 2 ,
(SEQ ID NO: 117)
[19CD]-isoGlu-RCNTATCATQRLAHFLHRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNTP-NH 2 ,
(SEQ ID NO: 118)
[19CD]-isoGlu-RCGTATCATERLANFLVRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 119)
[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 120)
[19CD]-isoGlu-RCGTATCATERLAHFLKRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 121)
[19CD]-isoGlu-RCNTATCATQRLAHFLHRSVF-Gly(Me)-A-
Ile(Me)-LSSTEVGSETP-NH 2 ,
(SEQ ID NO: 122)
[19CD]-isoGlu-RCNTATCATQRLAHFLHRVSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSETP-NH 2 ,
(SEQ ID NO: 123)
[19CD]-isoGlu-RCGTATCATERLAHFLVRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSETP-NH 2 ,
(SEQ ID NO: 124)
[19CD]-isoGlu-RCPTATCATDRLAHFLVRSSF-Gly(Me)-A-
Ile(Me)-LSSTDVGSDTP-NH 2 ,
(SEQ ID NO: 125)
[19CD]-isoGlu-RCNTATCATQRLAHFLVRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSETP-NH 2 ,
(SEQ ID NO: 126)
[19CD]-isoGlu-RCPTATCATDRLAHFLHRSSF-Gly(Me)-A-
Ile(Me)-LSSTDVGSNTP-NH 2 ,
(SEQ ID NO: 127)
[19CD]-isoGlu-RCGTATCATERLAHFLHRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSETP-NH 2 ,
(SEQ ID NO: 128)
[19CD]-isoGlu-RCPTATCATDRLAHFLHRSSF-Gly(Me)-A-
Ile(Me)-LSSTDVGSDTP-NH 2 ,
(SEQ ID NO: 129)
[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSST-Hyp-NH 2 ,
(SEQ ID NO: 130)
[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSST-Hyp-NH 2 ,
(SEQ ID NO: 131)
[19CD]-isoGlu-RCGTATCATERLAHFLHRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSST-Hyp-NH 2 ,
(SEQ ID NO: 132)
[19CD]-isoGlu-RCGTATCATERLAHFLVRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSST-Hyp-NH 2 ,
(SEQ ID NO: 133)
[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSFT-Hyp-NH 2 ,
(SEQ ID NO: 134)
[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSFT-Hyp-NH 2 ,
(SEQ ID NO: 135)
[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSSTP-NH 2 ,
(SEQ ID NO: 136)
[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSSTP-NH 2 ,
(SEQ ID NO: 137)
[19CD]-isoGlu-RCGTATCATERLAHFLERSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSSTP-NH 2 ,
(SEQ ID NO: 138)
[19CD]-isoGlu-RCGTATCATERLAHFLHRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSSTP-NH 2 ,
(SEQ ID NO: 139)
[19CD]-isoGlu-RCGTATCATERLAHFLVRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSSTP-NH 2 ,
(SEQ ID NO: 140)
[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSFTP-NH 2 ,
(SEQ ID NO: 141)
[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSFTP-NH 2 ,
(SEQ ID NO: 142)
[19CD]-isoGlu-RCGTATCATERLADFLTRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSST-Hyp-NH 2 ,
(SEQ ID NO: 143)
[19CD]-isoGlu-RCGTATCATERLADFLTRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSFT-Hyp-NH 2 ,
(SEQ ID NO: 144)
[19CD]-isoGlu-RCGTATCATERLA-Aad-FLTRSSF-Gly(Me)-
A-Ile(Me)-LSSTEVGSST-Hyp-NH 2 ,
(SEQ ID NO: 145)
[19CD]-isoGlu-RCGTATCATERLA-Aad-FLTRSSF-Gly(Me)-
A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH 2 ,
(SEQ ID NO: 146)
[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSST-Apr-NH 2 ,
(SEQ ID NO: 147)
[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSSTP-NH 2 ,
(SEQ ID NO: 148)
[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGS-Orn-TP-NH 2 ,
(SEQ ID NO: 149)
[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSTT-Hyp-NH 2 ,
(SEQ ID NO: 150)
[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 151)
[19CD]-isoGlu-RCNTATCATQRLAHFL-Aad-RSSF-Gly(Me)-
A-Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 152)
[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH 2 ,
(SEQ ID NO: 153)
[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSGT-Hyp-NH 2 ,
(SEQ ID NO: 154)
[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH 2 ,
(SEQ ID NO: 155)
[19CD]-isoGlu-RCGTATCATERLADFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 156)
[19CD]-isoGlu-RCGTATCATERLA-Aad-FLQRSSF-Gly(Me)-
A-Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 157)
[19CD]-isoGlu-RCNTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 158)
[19CD]-isoGlu-RCQTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 159)
[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 160)
[19CD]-isoGlu-RCPTATCATDRLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTDVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 161)
[19CD]-isoGlu-RCNTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSDT-Hyp-NH 2 ,
(SEQ ID NO: 162)
[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNTP-NH 2 ,
(SEQ ID NO: 163)
[19CD]-isoGlu-RCNTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNTP-NH 2 ,
(SEQ ID NO: 164)
[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 165)
[19CD]-isoGlu-RCPTATCATQRLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 166)
[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNTP-NH 2 ,
(SEQ ID NO: 167)
[19CD]-isoGlu-RCNTATCATERLADFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNTP-NH 2 ,
(SEQ ID NO: 168)
[19CD]-isoGlu-RCPTATCATERLADFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNTP-NH 2 ,
(SEQ ID NO: 169)
[19CD]-isoGlu-RCNTATCATERLADFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 170)
[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSST-Hyp-NH 2 ,
(SEQ ID NO: 171)
[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSST-Hyp-NH 2 ,
(SEQ ID NO: 172)
[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSGT-Hyp-NH 2 ,
(SEQ ID NO: 173)
[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSGT-Hyp-NH 2 ,
(SEQ ID NO: 174)
[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSTT-Hyp-NH 2 ,
(SEQ ID NO: 175)
[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSTT-Hyp-NH 2 ,
(SEQ ID NO: 176)
[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH 2 ,
(SEQ ID NO: 177)
[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH 2 ,
(SEQ ID NO: 178)
[19CD]-isoGlu-RCGTATCATERLAHFLQRF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 179)
[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNTP-NH 2 ,
(SEQ ID NO: 180)
[19CD]-isoGlu-RCNTATCATQRLAHFLQRF-Gly(Me)-A-
Ile(Me)-LSSTEVGSGT-Hyp-NH 2 ,
(SEQ ID NO: 181)
[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSGTP-NH 2 ,
(SEQ ID NO: 182)
[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSGT-Hyp-NH 2 ,
(SEQ ID NO: 183)
[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSTTP-NH 2 ,
(SEQ ID NO: 184)
[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSTT-Hyp-NH 2 ,
(SEQ ID NO: 185)
[19CD]-isoGlu-RCNTATCATQRLAHFLERSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSSTP-NH 2 ,
(SEQ ID NO: 186)
[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSSTP-NH 2 ,
(SEQ ID NO: 187)
[19CD]-isoGlu-RCNTATCATQRLA-Aad-FLQRSSF-
Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 188)
[19CD]-isoGlu-RCNTATCATQRLA-Aad-FLQRSSF-Gly(Me)-
A-Ile(Me)-LSSTEVGSST-Hyp-NH 2 ,
(SEQ ID NO: 189)
[19CD]-isoGlu-RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 190)
[19CD]-isoGlu-RCQTATCATDRLA-Aad-FLQRSSF-Gly(Me)-
A-Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 191)
[19CD]-isoGlu-RCQTATCATERLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSGT-Hyp-NH 2 ,
(SEQ ID NO: 192)
[19CD]-isoGlu-RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSGT-Hyp-NH 2 ,
(SEQ ID NO: 193)
[19CD]-isoGlu-RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNTP-NH 2 ,
(SEQ ID NO: 194)
[19CD]-isoGlu-RCQTATCATERLA-Aad-FLQRSSF-Gly(Me)-
A-Ile(Me)-LSSTEVGSNTP-NH 2 ,
(SEQ ID NO: 195)
[19CD]-isoGlu-RCQTATCATERLA-Aad-FLQRSSF-Gly(Me)-
A-Ile(Me)-LSSTEVGSGTP-NH 2 ,
(SEQ ID NO: 196)
[19CD]-isoGlu-RCQTATCATDRLA-Aad-FLQRF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNT-Hyp-NH 2 ,
(SEQ ID NO: 197)
[19CD]-isoGlu-RCQTATCATERLAHFLQRF-Gly(Me)-A-
Ile(Me)-LSSTEVGSNTP-NH 2 ,
wherein [19CD] represents [19-carboxynonadecanoyl];
or a pharmaceutically acceptable salt thereof.
27 . An amylin analogue according to claim 1 , comprising an intramolecular disulfide bridge formed between the cysteine residues present at positions 2 and 7 of the amino acid sequence.
28 . A pharmaceutical composition comprising an amylin analogue according to claim 1 , in combination with a pharmaceutically acceptable carrier, excipient or vehicle.
29 . A device comprising an amylin analogue according to claim 1 , for delivery of the amylin analogue to a subject.
30 . A kit comprising an amylin analogue according to claim 1 , and optionally further comprising packaging and instructions for use.
31 . (canceled)
32 . A method for the synthesis of an amylin analogue according to claim 1 .
33 . A method according to claim 32 comprising synthesizing the amylin analogue by solid-phase or liquid-phase methodology, optionally isolating and purifying the final product, and further optionally comprising the step of forming a disulfide bond between the thiol groups of the cysteine side chains at positions 2 and 7.
34 . (canceled)
35 . A method of treating, inhibiting or reducing weight gain, promoting weight loss, reducing food intake, and/or reducing excess body weight in a subject in need, said method comprising administering to said subject a therapeutically effective amount of an amylin analogue according to claim 1 .
36 . A method of treating obesity, morbid obesity, obesity prior to surgery, obesity-linked inflammation, obesity-linked gallbladder disease, obesity-induced sleep apnea and respiratory problems, degeneration of cartilage, osteoarthritis, or reproductive health complications of obesity or overweight such as infertility, in a subject in need, said method comprising administering to said subject a therapeutically effective amount of an amylin analogue according to claim 1 .
37 . (canceled)
38 . A method of prevention or treatment of Alzheimer's disease, diabetes, type 1 diabetes, type 2 diabetes, pre-diabetes, insulin resistance syndrome, impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease including metabolic syndrome, hyperglycemia, hypertension, atherogenic dyslipidemia, hepatic steatosis (“fatty liver”), kidney failure, arteriosclerosis (e.g. atherosclerosis), macrovascular disease, microvascular disease, diabetic heart (including diabetic cardiomyopathy and heart failure as a diabetic complication) coronary heart disease, peripheral artery disease or stroke, and combinations thereof in a subject in need, said method comprising administering to said subject a therapeutically effective amount of an amylin analogue according to claim 1 .
39 . A method of lowering circulating LDL levels and/or increasing HDL/LDL ratio, comprising administering an amylin analogue of claim 1 .
40 - 46 . (canceled)
47 . An amylin analogue according to claim 19 which is selected from the group consisting of:
(SEQ ID NO 102)
[19CD]-isoGlu-RCNTATCATQRLADFLHRSSF-Gly(Me)-A-
Ile(Me)-LSSTEVGSETP-NH 2 ;
(SEQ ID NO 105)
[19CD]-isoGlu-RCNTATCATQRLADFLHRSSNNF-Gly(Me)-A-
Ile(Me)-LSSTNVGSNT-Apr-NH 2 ;
and
(SEQ ID NO 106)
[19CD]-isoGlu-RCNTATCATQRLAHFLHRSSNNF-Gly(Me)-A-
Ile(Me)-LSSTNVGSNT-Apr-NH 2 ;
wherein [19CD] represents [19-carboxynonadecanoyl]:
or a pharmaceutically acceptable salt thereof.Join the waitlist — get patent alerts
Track US2021115104A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.